Bayer restructuring

Bayer announced last week that it will close its hemophilia manufacturing facility in Wuppertal, Germany, and lay off 350 workers. Its recombinant factor VIII production will take place at its site in Berkeley, California. The cuts in Germany come on top of the announced layoffs in October of more than 225 manufacturing workers in Berkeley.

Sandoz recalls losartan products

The first of a series of recalls involving blood pressure medication were in August. Months later, tainted drugs continue to be found in the US supply. The FDA and Sandoz have announced the recall of one lot of losartain blood pressure medicine that was manufactured by its Lek Pharmaceuticals unit in Ljubljana, Slovenia, because it contains N-nitrosodiethylamine (NDEA), a suspected carcinogen.

NDEA along with N-Nitrosodimethylamine (NDMA) are two probable human carcinogens that the FDA has discovered can be created during manufacturing under certain conditions.

Click here to view the entire article.

Regeneron’s Eylea generates over $1 billion in quarterly US sales

The third quarter US sales for Regeneron’s Eylea were listed as $1.02 billion. This is the first time the drug has generated over $1 billion in quarterly US sales. Q2 sales were $992 million. In August, Eylea received an FDA nod in wet age-related macular degeneration as a 12-week dosing formulation, and the agency is scheduled to decide on the drug’s use in diabetic retinopathy by May 13, 2019.